Cabinet Approves Airport At Kota-Bundi In Rajasthan For Rs 1,507 Crore
The Union Cabinet on Tuesday cleared a proposal to set up a new airport at Kota-Bundi in Rajasthan at an estimated cost of Rs 1,507 crore.
The airport, to be completed in two years, will have an annual passenger handling capacity of 2 million and 1,089 acres (around 440.06 hectares) of land is being provided free of cost by the Rajasthan government for the project.
Briefing the media after the Cabinet meeting, Information & Broadcasting Minister Ashwini Vaishnaw said the greenfield airport project at Kota-Bundi will be funded by the Airports Authority of India (AAI) through its internal accruals.
Kota-Bundi constituency is represented by Lok Sabha Speaker Om Birla.
The Cabinet Committee on Economic Affairs, chaired by Prime Minister Shri Narendra Modi, has approved the proposal for developing a green field airport at Kota-Bundi at an estimated cost of Rs 1,507 crore, according to an official release.
The state government has transferred 440.06 hectares of land to AAI for the airport, which will be suitable for the operation of narrow-body Airbus A321-type aircraft.
"The project includes construction of a terminal building spanning an area of 20,000 sqm capable of handling 1,000 Peak Hour Passengers (PHP) with annual capacity of 2 Million Passengers Per Annum (MPPA), Runway 11/29 of dimensions 3200m x 45m, Apron with 07 parking bays for A321 type aircraft, two Link Taxiways, ATC cum Technical Block, Fire Station, car park and allied works," the release said.
Vaishnaw said the airport will significantly improve regional connectivity and promote the local economy.
AAI will fund the project through its internal accruals and is expected to be completed in 24 months.
The new airport will be coming up around 23 kilometres away from the existing airport, Vaishnaw said.
According to the release, the existing Kota airport is owned by AAI but cannot be developed for commercial operations due to inadequate land availability and urbanisation around the airport.
The existing airport has a "runway (08/26) of dimensions 1220 m x 38 m, suitable for Code 'B' aircraft (such as DO-228), and an apron capable of accommodating two such aircraft. The terminal building spans an area of 400 sqm and is capable of handling 50 passengers during peak hours," it added.
Kota, situated on the banks of the Chambal River, is recognised as Rajasthan's industrial capital and is also known as the educational coaching hub of the country. "Kota's prominence in educational and industrial sectors makes the Greenfield Airport a critical infrastructure project, aimed at addressing the anticipated traffic growth in the region," the release said.
In the last 11 years, Vaishnaw said the number of operational airports in the country has more than doubled to 162 in 2025 from 74 in 2014.
Also, the number of air passengers has increased to 41.2 crore this year from 16.8 crore in 2014, he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
NSUI first to release manifesto, promises e-bike stations and mental health counselling
Chandigarh: Solar rooftops, subsidised canteens, 24×7 health centres, ramps and lifts, even e-scooter stations- NSUI opened the manifesto season at Panjab University with a catalogue of promises that sounded ambitious, but to many on campus, familiar. Tired of too many ads? go ad free now Last year's commitments of placements, self-defence classes and pad-vending machines still remain unfulfilled, and doubts are already circling whether this manifesto will fare any better. The Congress-backed student body released its document at Chandigarh Congress office, with NSUI national president Varun Choudhary and Chandigarh Congress chief H S Lucky present. Choudhary said the manifesto "reflected the aspirations of every student" and would help NSUI "sweep the elections." Asked how the long list would be assured, Lucky replied, "Manifesto means manifestation, and the motive is to strive for it. " The manifesto covers nearly every aspect of campus life: OBC reservation in admissions and hostels, scholarships for EWS students, a "One PU, One App" for grievances and results, 24×7 innovation hubs in unused classrooms, subsidised food with daily menu voting, women's safety desks, leadership programmes, sports scholarships, and more. Yet PU's lived reality points to a wide gap. As reported earlier this week, manifestos at PU "promise the moon but deliver not even an email ID." On disability access, NSUI talks of ramps and lifts. But even after a Punjab State Human Rights Commission directive and memorandums by students from 2023, PU still lacks a basic ramp at the SBI fee counter where every student queues, as reported in June. An accessibility audit in 2024 exposed further deficits, while last year's council chose to prioritise cultural fests instead. Tired of too many ads? go ad free now Women's safety is another major plank. NSUI promises a 24×7 task force, grievance desks and full CCTV coverage. But PU already struggles with inadequate security staff, and despite budget approval in December for CCTV expansion, installation is yet to begin. As TOI reported in July, even with the library buzzing 24×7, many women students avoid the dark, poorly lit roads leading back to their hostels. Mental health counselling, too, finds mention. But counselling is already mandatory under UGC norms, and PU has only one part-time counsellor for over 16,000 students- a crisis TOI exposed in July. Likewise, the pledge for a YouTube channel ignores that PU already runs one. With the university facing a financial crunch and still awaiting over Rs 47 crore for hostel construction, proposals like solar rooftops, e-scooter stations and 24×7 doctors sound more like slogans than plans. The much-touted "One PU, One App", pitched as a digital hub for results, grievances, library and transport- also seems a distant dream. PU councils have failed for years to provide students even a basic official email ID, despite repeated assurances in manifestos. Against that backdrop, an all-in-one app looks more like a distant hope than a deliverable. Choudhary admitted NSUI could only "pressurise" the administration, without explaining how the projects would move from manifesto to implementation. Still, by releasing its manifesto first, NSUI has forced other groups to catch up. Whether this document turns into delivery or another year of recycled paper promises is the question weighing on PU voters.
Economic Times
an hour ago
- Economic Times
Stock Radar: Bajaj Auto showing signs of reversal after falling over 30% from highs; medium term should ‘buy the dip'
Bajaj Auto Ltd, part of the automobile space, bounced back after taking support below the 100-DMA on the daily charts and is gradually moving traders with a high risk profile can look to buy the stock for a possible target of Rs 9,700 in the next 2-4 months, suggest 2-3-wheeler stock hit a high of Rs 12,772 on September 27, 2024, but it failed to hold the momentum. It closed at Rs 8,588 on August 18, 2025 which
Economic Times
an hour ago
- Economic Times
Aurobindo Pharma closing in on $5.5b Zentiva buyout
Boost to Aurobindo's European footprint Live Events Change of hands (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Mumbai: Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5-5.5 billion (Rs 43,500-47,900 crore) from Advent International , said several people aware of the matter, underscoring the growing consolidation of pharmaceutical assets in successful, this will be the largest-ever acquisition by an Indian pharma company, both at home and abroad, trumping the $3.2-billion acquisition of Daiichi Sankyo's stake in Ranbaxy in 2014, or Biocon Biologics' $3.3 billion cash and stock buyout of the global biosimilars business of US-based is competing with US private equity firm GTCR , the other serious contender left in the fray. Both sides are engaged in intense negotiations to finalise the various commercial and operations aspects of the late last year, Advent has been engaged with advisers Goldman Sachs and boutique investment bank PJT Partners to explore exit options for Zentiva, which it acquired seven years were made to several financial investors, including TPG and pharma competitors worldwide for a potential takeover.'The competition heated up from May. The binding offers have been submitted a few weeks ago and ongoing discussions have reached an advanced stage,' said a PE executive involved in the matter. 'Price is no longer being negotiated… A formal announcement can happen in the next fortnight or a month.'Zentiva will significantly boost Aurobindo's European footprint, specifically in the east European region–Czech Republic, Romania and Slovakia—where the market is seen as fertile and steadily warming up to a raft of biosimilars, following patent expiries of big prescription brands. Besides, as most healthcare spending in eastern Europe is led by government bulk public procurement, the returns are steadier as compared to perpetual price erosion in the revenues from Europe are already the highest among all other homegrown pharma peers. For calendar 2024, Zentiva Group's revenues were 1.7 billion euros ($1.98 billion) at an ebitda of 400 million euros ($467 million). Even then, analysts are surprised at the boldness of the bet that the Hyderabad-based company is willing to take amid heightened geopolitical risks and tariff market value stands at Rs 63,684.90 crore ($7.4 billion), whereas Zentiva is privately held. According to people aware of developments, Aurobindo has already secured a $4.75-billion credit line from MUFG–the sole financier in the transaction–as a bridge loan for the transaction. The remaining $800 million will be from the company's internal and Zentiva didn't respond to queries. Advent and MUFG declined to was the first to report on the Zentiva sale last November and on Aurobindo's interest in July this origins that can be traced back to Black Eagle Pharmacy from the 15th century, Zentiva was nationalised in 1946 and has undergone several ownership changes, including one in 1998 when the management team had taken over a majority share to refocus on branded generics. A decade later, in 2009, it got acquired by Sanofi and in 2018, got carved out by Advent for $2.4 billion, a deal process that had even seen a preliminary interest from India's Torrent the years, it has diversified its presence across categories such as prescription drugs, OTC products and consumer health and food supplements as well as geographies, growing both organically and through a series of buyouts across the region. It currently operates in 30 countries and has set a goal to reach one in five people across Europe by India, Zentiva has a manufacturing site in Gujarat. In 2022, Polish firm Pol Pharma, backed by a few private equity players, was reported to have placed a $3.5-billion bid for Zentiva, but the discussions remained inconclusive as the owners were reportedly considering a public leading drugmakers such as Biocon and, more recently, Lupin, have struck separate deals with Zentiva to push their biosimilars in the European region. Aurobindo is developing a robust pipeline of biosimilars such as denosumab (Prolia) for osteoporosis as well as omalizumab (Xolair) and bevacizumab (Avastin) for multiple cancer treatments.'While pricing pressure persists in chronic therapies, the European Union (EU) remains attractive for oncology and retail segments. Ongoing investments in EU-focused capacity continue to support volume growth,' said Amey Chalke of JM EU business of Aurobindo reported 9% revenue growth in the June quarter, from a year ago, with a strong performance across major markets and is on track to cross 1 billion euros in annual revenue in FY26. Injectables grew about 20% from the year earlier, driven by shortage-led demand. Two new oncology lines are being added to meet rising needs, as per the company also received four biosimilar approvals with commercial supplies initiated in the UK and full ramp-up expected in the third or fourth quarter of this fiscal. Aurobindo is targeting 40–60% margins in the EU biosimilar segment and aims for a blended 50% gross margin. Inhouse manufacturing now exceeds half the total formulations volumes, thereby boosting margins, inching toward 20% Aurobindo's FY25 consolidated sales of Rs 31,724 crore ($3.6 billion), the US market accounted for Rs 14,186 crore, up 6.8% from the year earlier. The European business grew 16.6% to Rs 8,356 month, Aurobindo acquired US-based contract development and manufacturing organization (CDMO) player Lannett for $250 million to shore up its manufacturing presence in the US while enhancing its capabilities in manufacturing complex generic drugs such as controlled at least three previous occasions, Aurobindo has either lost out to rivals or had to back out of marque transactions after announcing them. In 2020, it had to call off its deal to acquire the oral solids and dermatology business of Sandoz (part of Novartis) in the US for $900 million, failing to receive due approvals from US Federal Trade Commission even after two years.
